noscript

News and Announcements

CAVATAK Immunotherapy Combo shows more Anti-cancer Activity

  • Published October 01, 2014 1:49PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

ASX and Media Release, 30 September 2014

CAVATAK Immunotherapy Combination Demonstrates Superior Anti-cancer Activity Presented at the European society for medical oncology (ESMO) 2014 Congress

•Preclinical studies show CAVATAK combined with checkpoint inhibitor agents provides significantly greater anti-tumour activity than checkpoint inhibitors alone
•Data suggest an anti-tumour immune response
•Results strengthen CAVATAK ‘s potential role as combination therapy with checkpoint inhibitors, a major new class of anticancer immunotherapies

30 September 2014, Sydney, Australia: Viralytics Limited (ASX:VLA, OTC:VRACY) overnight announced at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid that preclinical studies have generated further evidence of improved CAVATAK anti-cancer activity when used in combination with immune checkpoint inhibitors, a new class of cancer immunotherapies with blockbuster potential. CAVATAK is a proprietary formulation of a common cold virus that hass been shown to preferentially infect and attack cancer cells.

To view the full ASX and Media Release please click here.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now